Clinical Trials Logo

Neuroendocrine clinical trials

View clinical trials related to Neuroendocrine.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01169649 Completed - PANCREAS Clinical Trials

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Start date: July 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test a new drug called MK-2206. This study is a phase II study. In cancer studies, a phase II study is to find out what effects, good and/or bad, a new treatment has against a certain type of cancer. MK-2206 is an oral medication known as a targeted therapy. By attaching to the target, we hope that MK-2206 may stop the cancer cells from further growth and dividing. This study will help find out if MK-2206 is a helpful drug when taken in patients with neuroendocrine tumor.

NCT ID: NCT00688623 Completed - Carcinoma Clinical Trials

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe

RAMSETE/CDE16
Start date: June 24, 2009
Phase: Phase 2
Study type: Interventional

To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.